STOCK TITAN

Conavi Medical Announces Five-Year Extension of Credit Facilities with Japan Lifeline

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Conavi Medical (CNVIF) signed an amendment with Japan Lifeline to extend the maturity of its senior secured credit facilities to April 2032. The amendment moves maturity back five years from April 2027. The annual interest rate will rise from 6.5% to 10%, but under unchanged terms, Conavi generally does not have to pay interest until maturity.

Conavi said the extension gives it more financial flexibility as it works to expand U.S. hospital placements of its OCTIV hybrid imaging system. The system received FDA 510(k) clearance, and Conavi completed its first U.S. commercial placement and clinical cases.

Loading...
Loading translation...
3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointJapan Lifeline credit amendment extends the maturity of Conavi’s senior secured facilities by five years, from April 2027 to April 2032
  • Minor point. Forward-looking: it has not happened yet and may not happen.U.S. hospital expansion is a stated priority for Conavi as it commercializes OCTIV
  • Minor point. Forward-looking: it has not happened yet and may not happen.Additional clinical evidence on hybrid imaging in coronary procedures is a stated priority for Conavi

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Annual interest rate on the credit facilities will increase from 6.5% to 10%

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Extension to April 2032 enhances financial flexibility as Conavi advances U.S. commercialization of OCTIV™

TORONTO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has entered into an amendment with Japan Lifeline Co., Ltd. (“Japan Lifeline”) extending the maturity of the Company’s existing senior secured credit facilities by five years, from April 2027 to April 2032.

The extension better aligns Conavi’s debt maturity profile with its commercial development plans following FDA 510(k) clearance and the completion of its first U.S. commercial placement and clinical cases with the OCTIV™ hybrid imaging system.

“Japan Lifeline has supported Conavi for more than a decade, and we appreciate its continued commitment as we advance commercialization,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “This extension gives us greater financial flexibility to build on our initial U.S. clinical and commercial milestones. Our focus is on expanding hospital placements, supporting physician adoption and generating additional clinical evidence demonstrating the value of hybrid imaging in coronary interventions.”

The interest rate under the credit facilities will increase from 6.5% to 10% per annum; however, consistent with the existing terms of the credit facilities, Conavi is generally not required to make any interest payments until maturity.  

Additional details regarding the amendment will be included in the Company’s regulatory filings on SEDAR+ at www.sedarplus.ca.

About Conavi Medical

Conavi Medical Corp. is a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Its OCTIV™ hybrid imaging system combines intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) to provide simultaneous, co-registered images of coronary arteries using a single imaging catheter. These complementary imaging modalities provide physicians with information to support treatment decisions during coronary interventions. For more information, visit www.conavi.com.

Forward looking information

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi's hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging, the ability of Conavi’s hybrid imaging system to meet market needs and Conavi’s plans for expanding hospital placements, supporting physician adoption and generating additional clinical evidence. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company's profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact

Mark Quick, Chief Financial Officer | 416-483-0100
Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When do Conavi Medical’s credit facilities with Japan Lifeline now mature?

Conavi Medical’s senior secured credit facilities now mature in April 2032, five years after the previous maturity of April 2027.

What interest rate will Conavi Medical pay under the Japan Lifeline credit amendment?

The interest rate on the facilities will increase to 10% per year from 6.5%. Under unchanged terms, Conavi generally does not have to make interest payments until maturity.

Keep reading